혈장 분획용 콜드체인 제품(Cold Chain Products) 시장은 2023년에는 5억 8,112만 달러로 평가되었고, 2029년까지 예측 기간에는 CAGR 4.63%로 눈부신 성장을 이룰 것입니다.
혈장 분획용 콜드체인 제품은 공급 체인 공정 전체에서 혈장 유래 제품의 무결성, 안전성 및 효능을 유지하는 데 필수적인 특수 장비, 재료 및 기술을 포함합니다. 여기에는 수집부터 유통, 투여까지 모두 포함됩니다. 혈장 분획에서는 혈장을 면역글로불린, 알부민, 응고 인자 등 다양한 성분으로 분리하여 다양한 의학적 상태의 치료용 제품을 제조하는데 이용합니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2025-2029년 |
| 2023년 시장 규모 | 5억 8,112만 달러 |
| 2029년 시장 규모 | 7억 6,422만 달러 |
| CAGR 2024-2029년 | 4.63% |
| 급성장 부문 | 병원과 수혈 |
| 최대 시장 | 북미 |
이러한 콜드체인 제품의 중요한 구성 요소는 혈장 유래 제품을 저장하는 데 필요한 온도 조건을 유지하는 데 필수적인 냉장 장치 및 냉동 장치를 포함합니다. 이러한 장치는 혈장 성분의 열화를 방지하고 제품의 품질을 유지하기 위해 혈장 성분이 지정된 온도 범위 내에 유지되도록 합니다. 또한, 데이터 로거 및 디지털 온도계와 같은 온도 모니터링 장치는 보관 및 운송 중 온도 조건을 모니터링하는 데 사용됩니다. 이 장비는 실시간 온도 측정 및 경고를 제공하여 온도 이상을 신속하게 식별하고 해결할 수 있습니다.
단열 용기, 보온 담요, 온도 제어 포장과 같은 콜드체인 포장 재료는 운송 중 온도 변화로부터 혈장 유래 제품을 보호하는 역할을합니다. 이 단열 포장은 안정된 온도 조건을 유지하고 불리한 환경 조건으로부터 제품을 보호합니다. 콜드체인 제품과 솔루션 진보로 혁신적인 온도 모니터링 장비, 냉동 시스템 및 포장 재료가 개발되었습니다. 이러한 진보는 혈장 분획의 콜드체인 물류의 효율성, 신뢰성, 안전성을 높이고 시장 성장을 가속합니다. 혈장 유래 치료에 대한 수요가 증가함에 따라 혈장 채취 및 분획 작업도 증가합니다. 결과적으로, 혈장 분획 시설은 처리, 보관 및 수송을 통해 혈장 성분의 품질과 효과를 유지하기 위해 견고한 콜드체인 인프라가 필요합니다. 혈장 유래 제품의 품질과 안전성을 유지하는 것은 헬스케어 분야에서 가장 중요하며, 콜드체인 제품은 환자가 안전하고 효과적인 치료를 받을 수 있도록 하는데 매우 중요한 역할을 합니다.
콜드체인 기술 진보
혈장 채취·분획 작업 증가
제품의 품질과 환자의 안전성에 대한 관심 증가
온도 무결성 유지
비용 압력
혈장 분획 시설의 확대
최종 사용자별 인사이트
지역별 인사이트
Global Cold Chain Products Market for Plasma Fractionation was valued at USD 581.12 million in 2023 and will see an impressive growth in the forecast period at a CAGR of 4.63% to 2029. Cold chain products for plasma fractionation encompass specialized equipment, materials, and technologies essential for preserving the integrity, safety, and effectiveness of plasma-derived products throughout the supply chain process. This includes everything from collection to distribution and administration. Plasma fractionation involves separating plasma into its various components, such as immunoglobulins, albumin, and clotting factors, which are then utilized to create therapeutic products for treating diverse medical conditions.
| Market Overview | |
|---|---|
| Forecast Period | 2025-2029 |
| Market Size 2023 | USD 581.12 Million |
| Market Size 2029 | USD 764.22 Million |
| CAGR 2024-2029 | 4.63% |
| Fastest Growing Segment | Hospitals and Transfusion |
| Largest Market | North America |
Vital components of these cold chain products include refrigeration units and freezers, crucial for maintaining the requisite temperature conditions required for storing plasma-derived products. These units ensure that plasma components remain within the specified temperature range to prevent degradation and uphold product quality. Additionally, temperature monitoring devices, like data loggers and digital thermometers, are employed to oversee temperature conditions during storage and transportation. These devices offer real-time temperature readings and alerts, ensuring prompt identification and resolution of temperature excursions.
Cold chain packaging materials, such as insulated containers, thermal blankets, and temperature-controlled packaging, serve to safeguard plasma-derived products from temperature fluctuations during transit. These packaging solutions maintain stable temperature conditions and offer thermal insulation to shield against adverse environmental conditions. Advancements in cold chain products and solutions have resulted in the development of innovative temperature monitoring devices, refrigeration systems, and packaging materials. These advancements enhance the efficiency, reliability, and safety of cold chain logistics for plasma fractionation, thereby propelling market growth. With the escalating demand for plasma-derived therapies worldwide, there has been a corresponding rise in plasma collection and fractionation activities. Consequently, plasma fractionation facilities necessitate robust cold chain infrastructure to sustain the quality and efficacy of plasma components throughout processing, storage, and transportation. Maintaining the quality and safety of plasma-derived products is paramount in the healthcare sector, and cold chain products play a pivotal role in ensuring that patients receive treatments that are both safe and effective.
Key Market Drivers
Advancements in Cold Chain Technologies
Modern cold chain solutions incorporate advanced temperature monitoring devices that provide real-time data on temperature conditions throughout the supply chain. These devices offer greater accuracy and precision in monitoring temperature fluctuations, allowing for timely intervention in case of deviations. The Internet of Things (IoT) has revolutionized cold chain management by enabling the integration of sensors and connectivity solutions into refrigeration units, storage facilities, and transportation vehicles. IoT-enabled devices collect and transmit data on temperature, humidity, and other environmental variables, facilitating remote monitoring and control of cold chain operations. Innovations in cold chain packaging materials have led to the development of lightweight, durable, and environmentally sustainable solutions. Advanced packaging designs incorporate insulating materials, phase change materials (PCMs), and vacuum insulation panels (VIPs) to maintain stable temperature conditions and protect temperature-sensitive products from external factors.
Cold chain logistics rely on both active and passive refrigeration systems to maintain the required temperature range during transportation and storage. Advances in refrigeration technology have led to the development of energy-efficient systems that minimize power consumption while ensuring optimal temperature control. Cold chain management software solutions provide end-to-end visibility and control over cold chain operations, from inventory management to route optimization and compliance monitoring. These software platforms utilize data analytics, machine learning algorithms, and predictive modeling to optimize logistics processes and mitigate risks associated with temperature excursions.
Blockchain technology offers enhanced traceability and transparency in the cold chain by creating an immutable record of product movement and temperature data at each stage of the supply chain. Blockchain-based platforms enable stakeholders to verify the authenticity and quality of temperature-sensitive products, reducing the risk of counterfeit or compromised goods entering the supply chain. Cold chain technologies now include environmental monitoring and control systems that regulate temperature, humidity, and other environmental factors within storage facilities and transportation vehicles. These systems help prevent product degradation and ensure compliance with regulatory requirements for temperature-sensitive products. This factor will help in the development of the Global Cold Chain Products Market.
Rise in Plasma Collection and Fractionation Activities
As the demand for plasma-derived therapies grows globally, there's a corresponding increase in the volume of plasma collected and processed for fractionation. More plasma collection centers and fractionation facilities are established to meet this demand, leading to a higher requirement for cold chain products to ensure the integrity and safety of plasma components throughout the supply chain. Plasma collection and fractionation activities often involve multiple stages and locations, including collection centers, processing facilities, storage warehouses, and distribution centers. Cold chain products, such as refrigeration units, temperature monitoring devices, and packaging materials, are essential for maintaining the required temperature conditions during transportation and storage across these diverse locations.
Regulatory agencies impose stringent standards for the storage and handling of plasma-derived products to ensure product safety and efficacy. Compliance with these regulations necessitates the use of reliable cold chain solutions to maintain the integrity of plasma components and comply with temperature control requirements throughout the supply chain. Preserving the quality and efficacy of plasma-derived therapies is paramount to ensure patient safety and treatment effectiveness. Cold chain products play a crucial role in safeguarding the quality of plasma components by preventing temperature excursions and maintaining the required temperature range during storage and transportation.
Plasma-derived therapies are distributed globally to meet the needs of patients in various regions and countries. Establishing robust cold chain networks enables manufacturers to safely transport plasma products over long distances while ensuring product quality and compliance with regulatory standards. Advancements in cold chain technologies, such as temperature monitoring devices, refrigeration systems, and packaging materials, enhance the efficiency and reliability of cold chain logistics for plasma fractionation. These advancements enable precise temperature control, real-time monitoring, and proactive intervention to mitigate risks associated with temperature fluctuations. This factor will pace up the demand of the Global Cold Chain Products Market.
Growing Focus on Product Quality and Patient Safety
Plasma-derived therapies are highly sensitive to temperature fluctuations and improper storage conditions. Maintaining the required temperature range throughout the supply chain is essential to preserve the integrity and efficacy of plasma components. Cold chain products, such as refrigeration units, temperature monitoring devices, and packaging materials, help prevent temperature excursions and ensure product quality during transportation and storage. Regulatory agencies, such as the FDA (Food and Drug Administration) in the United States and the EMA (European Medicines Agency) in Europe, enforce strict guidelines for the storage and handling of plasma-derived products. Compliance with these regulations requires the implementation of robust cold chain solutions to maintain product quality and safety standards throughout the distribution process.
Proper cold chain management reduces the risk of product contamination and degradation, which can compromise the safety and efficacy of plasma-derived therapies. Cold chain products help mitigate risks associated with exposure to adverse environmental conditions, ensuring that plasma components remain viable and safe for patient use. The quality and safety of plasma-derived therapies directly impact patient outcomes and treatment effectiveness. By ensuring the integrity of plasma products through stringent temperature control measures, cold chain products contribute to improved patient safety, treatment efficacy, and overall healthcare outcomes.
Healthcare providers and patients rely on the integrity and safety of plasma-derived therapies to effectively manage medical conditions and improve quality of life. A robust cold chain infrastructure instills trust and confidence in the quality of plasma products, strengthening the reputation of manufacturers and distributors within the healthcare industry. Temperature excursions and improper handling can result in product losses and wastage, leading to financial losses for manufacturers and healthcare facilities. Cold chain products help minimize product losses by maintaining optimal storage conditions and preventing deterioration of plasma components, thus optimizing resource utilization, and minimizing wastage. This factor will accelerate the demand of the Global Cold Chain Products Market.
Key Market Challenges
Maintaining Temperature Integrity
Plasma-derived products, such as immunoglobulins, clotting factors, and albumin, are highly sensitive to temperature variations. Even minor deviations from the recommended temperature range during storage and transportation can compromise the efficacy and safety of these products. Regulatory agencies, including the FDA (Food and Drug Administration) in the United States and the EMA (European Medicines Agency) in Europe, have strict guidelines for the storage and handling of plasma-derived products. Compliance with these regulations requires meticulous temperature control throughout the entire cold chain process. The plasma fractionation supply chain involves multiple stakeholders, including plasma collection centers, fractionation facilities, distributors, and healthcare providers. Coordinating temperature control measures across diverse geographic locations and transportation modes presents logistical challenges that can impact temperature integrity. External environmental factors, such as ambient temperature variations, humidity levels, and exposure to sunlight, can affect the temperature integrity of plasma-derived products during storage and transportation. Controlling these environmental factors and mitigating their impact on product quality require robust cold chain infrastructure and management practices.
Cost Pressures
Maintaining a robust cold chain infrastructure, including temperature-controlled storage facilities, refrigeration units, and transportation systems, incurs high operational expenses. The investment required for purchasing, installing, and maintaining cold chain equipment and facilities contributes to overall operational costs. Implementing advanced cold chain technologies, such as temperature monitoring devices, data loggers, and refrigeration systems, involves significant upfront costs. Additionally, ongoing investments may be necessary to upgrade and replace outdated equipment to ensure compliance with regulatory standards and industry best practices. Ensuring the quality and safety of plasma-derived products throughout the cold chain requires adherence to stringent quality assurance standards and regulatory requirements. Quality control measures, including product testing, validation studies, and documentation, incur additional costs for manufacturers and distributors. Regulatory agencies impose strict guidelines for the storage, handling, and transportation of plasma-derived products to ensure product safety and efficacy. Compliance with these regulations requires investment in training, quality management systems, and audit procedures to demonstrate adherence to regulatory standards.
Key Market Trends
Expansion of Plasma Fractionation Facilities
The growing demand for plasma-derived therapies, such as immunoglobulins, albumin, and clotting factors, is driving the need for expanded plasma fractionation facilities. These facilities are essential for processing plasma collected from donors into various therapeutic products used to treat a wide range of medical conditions. The global population is growing, and the aging population is increasing the incidence of chronic diseases and medical conditions that require plasma-derived therapies. As the demand for these therapies continues to rise, plasma fractionation facilities must expand to meet the growing production needs. Technological advancements in plasma fractionation technology have increased production efficiency and capacity, allowing facilities to process larger volumes of plasma more rapidly. Expanded facilities can take advantage of these advancements to increase production output and meet market demand. Plasma fractionation facilities are expanding to diversify their product portfolios and offer a wider range of plasma-derived therapies to address evolving patient needs. The expansion allows facilities to produce new and innovative therapies while maintaining production levels of existing products.
Segmental Insights
End User Insights
The Hospitals and transfusion centers segment is projected to experience rapid growth in the Global Cold Chain Products Market for Plasma Fractionation during the forecast period. Hospitals and transfusion centers are key entities involved in the storage and distribution of blood and blood products, including plasma-derived therapies. With the rising prevalence of chronic diseases, surgical procedures, and traumatic injuries requiring blood transfusions, the demand for cold chain products to maintain the integrity of these products is growing. Healthcare infrastructure, including hospitals and transfusion centers, is expanding globally, particularly in emerging markets and developing regions. As healthcare systems improve and access to medical facilities increases, the demand for cold chain products to support blood and plasma storage and transportation also rises. Technological advancements in medical diagnostics, therapies, and treatments have increased the demand for specialized blood products and plasma-derived therapies. These advancements require stringent temperature control and monitoring during storage and transportation, driving the need for reliable cold chain products.
Regional Insights
North America emerged as the dominant region in the Global Cold Chain Products Market for Plasma Fractionation in 2023. North America boasts a well-developed healthcare infrastructure with advanced facilities for plasma collection, fractionation, and distribution. The region's robust healthcare system enables efficient handling and transportation of plasma-derived products while maintaining the required temperature conditions. North American companies have been at the forefront of developing and implementing innovative cold chain technologies and solutions. This includes temperature monitoring devices, refrigeration systems, and packaging materials designed to ensure the integrity and safety of plasma-derived products throughout the supply chain. Regulatory agencies in North America, such as the FDA (Food and Drug Administration) in the United States and Health Canada, enforce stringent standards for the production, storage, and distribution of plasma-derived therapies. Compliance with these regulations necessitates sophisticated cold chain infrastructure and quality assurance processes, which North American companies are adept at implementing.
B Medical Systems Sarl
Blue Star Limited
Thermo Fisher Scientific Inc.
Godrej and Boyce Manufacturing Co. Ltd.
Haier Biomedical
Eppendorf SE
Avantor, Inc.
Biolife Solutions Inc.
Helmer Scientific Inc.
In this report, the Global Cold Chain Products Market for Plasma Fractionation has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
United States
Canada
Mexico
Germany
United Kingdom
France
Italy
Spain
China
Japan
India
Australia
South Korea
Brazil
Argentina
Colombia
South Africa
Saudi Arabia
UAE
Company Profiles: Detailed analysis of the major companies present in the Global Cold Chain Products Market for Plasma Fractionation.
Global Cold Chain Products Market for Plasma Fractionation report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Detailed analysis and profiling of additional market players (up to five).